Syncona Share Price, News & Analysis (LON:SYNC) GBX 124.40 -0.80 (-0.64%) (As of 04:35 PM ET) Add Compare Share Share Today's Range 124.20▼ 12650-Day Range 106.20▼ 13552-Week Range 105▼ 197Volume375,965 shsAverage Volume608,443 shsMarket Capitalization£832.57 millionP/E RatioN/ADividend Yield1.61%Price TargetGBX 230 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsHeadlinesInsider TradesStock AnalysisAnalyst ForecastsChartCompetitorsHeadlinesInsider Trades Syncona MarketRank™ Stock AnalysisAnalyst RatingBuy3.00 Rating ScoreUpside/Downside83.7% UpsideGBX 230 Price TargetShort InterestN/ADividend StrengthWeakBased on Four FactorsSustainabilityN/ANews Sentiment0.57Based on 3 Articles This WeekInsider TradingN/AProj. Earnings GrowthN/ASee Full Details Hide Full Details Overall MarketRank™MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.2.10 out of 5 stars 3.5 Analyst's Opinion Consensus RatingSyncona has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 1 buy rating, no hold ratings, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of GBX 230, Syncona has a forecasted upside of 83.7% from its current price of GBX 125.21.Amount of Analyst CoverageSyncona has only been the subject of 1 research reports in the past 90 days. Previous Next N/A Short Interest Short InterestThere is no current short interest data available for SYNC. Previous Next 0.8 Dividend Strength Dividend YieldSyncona pays a meaningful dividend of 1.04%, higher than the bottom 25% of all stocks that pay dividends.Dividend GrowthSyncona does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for SYNC. Previous Next 2.5 News and Social Media Coverage News SentimentSyncona has a news sentiment score of 0.57. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Financial Services companies.News Coverage This WeekMarketBeat has tracked 3 news articles for Syncona this week, compared to 0 articles on an average week.Search Interest3 people have searched for SYNC on MarketBeat in the last 30 days. Previous Next 1.7 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Syncona insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 2.20% of the stock of Syncona is held by insiders.Percentage Held by Institutions70.76% of the stock of Syncona is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 0.6 Earnings and Valuation Price to Earnings Ratio vs. the MarketThe P/E ratio of Syncona is -1,565.10, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Syncona is -1,565.10, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioSyncona has a P/B Ratio of 0.67. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here About Syncona Stock (LON:SYNC)Syncona Limited is a fund specializes in investments in hedge, equity and long-term alternative investment funds across multiple asset classes. It manages private equity, debt, fixed income and alternative investments. The fund prefers to invest in healthcare and life sciences sector with focus on Cell therapy, gene therapy, biologics and small molecules. The fund invests in the public equity and fixed income markets across the globe. It targets attractive medium to long term returns by investing in leading long-only and alternative investment funds with proven managers and across multiple asset classes. The firm invests in separately managed account portfolios.Read More SYNC Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart SYNC Stock News HeadlinesDecember 5, 2023 | americanbankingnews.comSyncona's (SYNC) "Buy" Rating Reaffirmed at Numis SecuritiesDecember 4, 2023 | markets.businessinsider.comSyncona Portfolio Firm Beacon's AGTC-501 Trial Shows Positive Data In X-Linked Retinitis PigmentosaDecember 7, 2023 | Autonomix (Ad)How to Invest Early In the Next Potential Breakthrough Nerve-Sensing TechnologyAutonomix is preparing a public listing as they develop technology to potentially detect and treat a range of nervous system disorders with much greater visibility than available today. Now, their management team sees a potentially untapped $100B market opportunity.* *Disclosure: This is a paid advertisement for Autonomix’s Regulation A+ Offering. Please read the offering circular at invest.autonomix.comNovember 23, 2023 | msn.comBRIEF-Syncona Ltd To Acquire Freeline TherapeuticsNovember 22, 2023 | marketwatch.comFreeline Therapeutics Shares Rise on Takeover by SynconaNovember 22, 2023 | msn.comGene Therapy Player Freeline Therapeutics Goes Private In $28M DealNovember 22, 2023 | marketwatch.comFreeline Therapeutics Agrees to Buyout by SynconaNovember 22, 2023 | markets.businessinsider.comFreeline Therapeutics To Be Bought By Syncona For $28.3 Mln In Cash; Freeline Stock UpDecember 7, 2023 | Autonomix (Ad)How to Invest Early In the Next Potential Breakthrough Nerve-Sensing TechnologyAutonomix is preparing a public listing as they develop technology to potentially detect and treat a range of nervous system disorders with much greater visibility than available today. Now, their management team sees a potentially untapped $100B market opportunity.* *Disclosure: This is a paid advertisement for Autonomix’s Regulation A+ Offering. Please read the offering circular at invest.autonomix.comNovember 22, 2023 | msn.comFreeline Therapeutics to be acquired by Syncona for $28.3M in cashNovember 22, 2023 | finance.yahoo.comSyncona to Acquire Freeline TherapeuticsNovember 16, 2023 | lse.co.ukSyncona reports declining asset value as investment head steps downOctober 18, 2023 | markets.businessinsider.comSyncona Proposes To Acquire Freeline TherapeuticsOctober 18, 2023 | msn.comFreeline gains on non-binding buyout offer from SynconaOctober 18, 2023 | marketwatch.comSyncona Seeks to Buy Remaining Shares of Freeline TherapeuticsOctober 16, 2023 | finance.yahoo.comSwanBio Evolves Leadership Team with Appointment of Executive Chair and Chief Operating OfficerOctober 16, 2023 | marketwatch.comSyncona Portfolio Company to Present Updated Data on Cancer StudyOctober 4, 2023 | finanznachrichten.deSwanBio Therapeutics: SwanBio Advances to Higher-Dose Cohort in First-in-Human Study of Gene Therapy for AdrenomyeloneuropathyOctober 4, 2023 | finance.yahoo.comSwanBio Advances to Higher-Dose Cohort in First-in-Human Study of Gene Therapy for AdrenomyeloneuropathySeptember 29, 2023 | marketwatch.comSyncona to Buy Back Up to GBP40 Mln in SharesSeptember 27, 2023 | tmcnet.comForcefield Therapeutics appoints John Tsai MD as Chief Executive OfficerSeptember 12, 2023 | msn.comNovartis recalls Sandimmune oral solution due to crystal formationSeptember 11, 2023 | uk.investing.comFTSE 250 movers: Vistry surges, Syncona sinks on write-offSeptember 11, 2023 | thetimes.co.ukSyncona downcast as eye treatment is discontinuedSeptember 11, 2023 | uk.finance.yahoo.comUK's Syncona writes off 54.5 million stg after Novartis ends Gyroscope's therapySeptember 11, 2023 | lse.co.ukSyncona suffers negative valuation hit as Novartis discontinues GT005September 11, 2023 | reuters.comUPDATE 1-UK Stocks-Factors to watch on Sept 11See More Headlines Receive SYNC Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Syncona and its competitors with MarketBeat's FREE daily newsletter. Email Address Industry, Sector and Symbol Stock ExchangeLON Industry Asset Management Sub-IndustryN/A SectorFinancial Services Current SymbolLON:SYNC Previous SymbolLON:BACT CUSIPN/A CIKN/A Webwww.bacitltd.com Phone17168531362FaxN/AEmployees1,208Year FoundedN/APrice Target and Rating Average Stock Price TargetGBX 230 High Stock Price TargetGBX 230 Low Stock Price TargetGBX 230 Potential Upside/Downside+83.7%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage1 Analysts Profitability EPS (Most Recent Fiscal Year)GBX (0.08) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income£-56,020,000.00 Net MarginsN/A Pretax MarginN/A Return on Equity-4.37% Return on Assets-2.47% Debt Debt-to-Equity Ratio64.05 Current Ratio0.74 Quick Ratio0.53 Sales & Book Value Annual Sales£-39,790,000.00 Price / Sales-21.06 Cash FlowGBX 106.60 per share Price / Cash Flow1.17 Book ValueGBX 187 per share Price / Book0.67Miscellaneous Outstanding Shares669,270,000Free FloatN/AMarket Cap£837.93 million OptionableNot Optionable Beta0.31 Elon Musk's Next MoveWondering when you'll finally be able to invest in SpaceX, StarLink or The Boring Company? Click the link below to learn when Elon Musk will let these companies finally IPO.Get This Free Report Key ExecutivesMr. Thomas Henderson (Age 57)Co-Founder & Non-Exec. Director Dr. Martin Patrick Murphy Ph.D. (Age 55)Chief Exec. Officer Mr. John McDonald (Age 58)Co-Founder Mr. Rolf Kristian Berndtson Soderstrom ACA (Age 57)BA, Chief Financial Officer Mr. Ben WoolvenBus. Strategy and Operations PartnerDr. Christopher J. Hollowood Ph.D. (Age 48)CIO & Managing Partner of Syncona Investment Management Ltd. Ms. Annabel ClarkHead of Investor Relations and CommunicationsMr. Andrew CossarGen. CounselMs. Fenella DernieExec. OfficerMr. Edward Eliot Hodgkin DPhil (Age 60)Managing Partner More ExecutivesKey CompetitorsFidelity Special ValuesLON:FSVICG Enterprise TrustLON:ICGTIntegraFinLON:IHPEuropean Opportunities TrustLON:EOTMurray Income TrustLON:MUTView All Competitors SYNC Stock Analysis - Frequently Asked Questions Should I buy or sell Syncona stock right now? 1 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Syncona in the last twelve months. There are currently 1 buy rating for the stock. The consensus among Wall Street research analysts is that investors should "buy" SYNC shares. View SYNC analyst ratings or view top-rated stocks. What is Syncona's stock price target for 2024? 1 analysts have issued 1-year price objectives for Syncona's shares. Their SYNC share price targets range from GBX 230 to GBX 230. On average, they expect the company's share price to reach GBX 230 in the next twelve months. This suggests a possible upside of 83.7% from the stock's current price. View analysts price targets for SYNC or view top-rated stocks among Wall Street analysts. How have SYNC shares performed in 2023? Syncona's stock was trading at GBX 181 at the beginning of the year. Since then, SYNC shares have decreased by 30.8% and is now trading at GBX 125.21. View the best growth stocks for 2023 here. Is Syncona a good dividend stock? Syncona (LON:SYNC) pays an annual dividend of GBX 2 per share and currently has a dividend yield of 1.04%. Read our dividend analysis for SYNC. What other stocks do shareholders of Syncona own? Based on aggregate information from My MarketBeat watchlists, some companies that other Syncona investors own include Rexahn Pharmaceuticals (REXN), Barrick Gold (ABX), Agnico Eagle Mines (AEM), Franco-Nevada (FNV), Goldex Resources (GDX), VanEck Gold Miners ETF (GDX), Goldcorp (GG), Barrick Gold (GOLD) and Northern Dynasty Minerals (NAK). How do I buy shares of Syncona? Shares of SYNC stock and other U.K. stocks can be purchased through online brokerage accounts that support trading on the London Stock Exchange (LSX). Some U.K. companies can be purchased through major U.S. brokerages in the form of American Depository Receipts (ADRs), which are placeholder equities held in a trust by a bank that represent shares of a foreign stock.Compare Top Brokerages Here. This page (LON:SYNC) was last updated on 12/7/2023 by MarketBeat.com Staff Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Syncona Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.